SUO 2015 Annual Meeting at the AUA
Saturday, May 16, 2015
New Orleans Ernest N. Morial Convention Center: La Nouvelle AB
New Orleans, LA

SUO Reception with
Awards & Announcements
Hilton New Orleans Riverside
5:30 p.m. – 7:30 p.m.
5:45 p.m.  Awards & Announcements
SUO/SBUR: Emerging Paradigms in Metastasis
8:00 a.m. – 11:30 a.m.

Welcome
Introducers: Leonard G. Gomella, MD, FACS
Gail S. Prins, PhD

Challenges Faced with Re-Emerging Cancers
Michael Louis Cher, MD

Tumor Dormancy: The Hematopoietic Stem Cell Niche Regulates Dormancy
Russell Taichman, DMD, DMSc

mTOR Inhibitors in Metastatic Renal Cancer – Do They Work and When Do They Work?
Robert A. Figlin, MD

Epithelial-Mesenchymal-Transition: The Therapeutic Potential of Targeting the Epithelial-Mesenchymal Transition in Cancer
Fazlul H. Sarkar, PhD

Break

Circulating Tumor Cells: Telling the Truth about Metastasis
Speaker: Massimo Cristofanilli, MD

Pre-metastatic Niche: Breast Fibroblasts Modulate Early Dissemination, Tumorigenesis, and Metastasis through Alteration of Extracellular Matrix Characteristics
Speaker: Thea D. Tlsty, PhD

Debate: The Clonality of Prostate Cancer Metastases – Multiple or Single Origins?
Moderator: Natasha Kyprianou, MD, PhD
Debaters: Francesca Demicheli, PhD
Srinivasan Yegnasubramanian, MD, PhD

Donald S. Coffey Lecture: Cancer Stem Cells
Philip Beachy, PhD

Philip Beachy, PhD is the Ernest and Amelia Gallo Professor at Stanford University School of Medicine in the Departments of Biochemistry and Developmental Biology, and is a member of the Institute of Stem Cell Biology and Regenerative Medicine. He received a PhD in biochemistry at Stanford University School of Medicine and spent two years as staff associate at the Carnegie Institution’s Department of Embryology. He was previously a Professor of Molecular Biology and Genetics at Johns Hopkins University School of Medicine. Dr. Beachy has been an Investigator of the Howard Hughes Medical Institute since 1988, has been elected a member of the National Academy of Sciences (2002), and is a fellow of the American Academy of Arts and Sciences (2003), and of the American Association for the Advancement of Science (2001). His work has been recognized by many awards, including the National Academy of Sciences Award in Molecular Biology (1998), the March of Dimes Prize in Developmental Biology (2008), and the Keio Medical Science Prize (2011).

11:30 a.m. - 12:30 p.m. SUO Business Meeting Luncheon
SUO Members Only

2015 SUO Annual Meeting at the AUA
12:30 p.m. – 5:00 p.m.

Welcome and Introductions
David F. Jarrard, MD

Young Investigator Award Program
Stuart Holden, MD

Whitmore Lecture: The Emperor’s New Clothes Bias in Urologic Science
Ian M. Thompson, Jr., MD
Introducer: J. Brantley Thrasher, MD

12:40 p.m. - 1:00 p.m. Evaluating the Risk Locally Advanced and Micrometastatic Bladder Cancer Prior to Cystectomy
Moderator: Tracy M. Downs, MD

1:00 p.m. - 1:10 p.m. Role Contemporary Pre-Cystectomy Nomograms at Predicting Locally Advanced and Metastatic Urothelial Bladder Cancer
Wassim Kassouf, MD

1:10 p.m. - 1:20 p.m. Pathologic Assessment at the Time of TURBT: Can Your Initial Pathology Report Be Trusted When Making Treatment Decisions
Donna Hansel, MD, PhD

1:20 p.m. - 1:30 p.m. Opportunities in PET and PET/MRI for Bladder Cancer
Steve Y. Cho, MD

1:30 p.m. - 1:40 p.m. Liquid Biopsy Circulating Tumor Cells as Biomarkers for Advanced Urothelial Carcinoma
Trinity J. Bivalacqua, MD, PhD

SUO 2015 Annual Meeting at the AUA
12:30 p.m. – 5:00 p.m.

Ian M. Thompson, Jr., MD has published over 400 scientific papers, several-dozen book chapters and has edited five textbooks in medicine and surgery. He previously served as Chair of the Residency Review Committee for Urology and currently serves as Vice-Chair of the Early Detection Research Network of the National Cancer Institute. He previously served as the President of the Society of Urologic Oncology. He currently serves as Chair of the Genitourinary Committee of the Southwest Oncology Group, the largest clinical trials organization supported by the National Cancer Institute. He has served as a visiting professor at most major academic institutions in the US as well as at many leading cancer centers in Europe, Asia, Central and South America as well as Australia.
1:40 p.m. - 1:50 p.m.  Case Discussion: Assessing the High Risk Patient  
Moderator: Tracy M. Downs, MD  
Panelists: Trinity J. Bivalacqua, MD, PhD  
Donna Hansel, MD, PhD  
Wassim Kassouf, MD  
Steve Y. Cho, MD

3:40 p.m. - 3:55 p.m.  Debate: Neoadjuvant vs. Adjuvant Systemic Chemotherapy for Penile Cancer Patients with Bulky Inguinal Adenopathy (cN2/3) in the Absence of Occult Sites of Metastases  

Pro- Adjuvant Chemotherapy  
Debater: Mayer N. Fishman, MD, PhD

Pro- Neoadjuvant Chemotherapy  
Debater: Lance C. Pagliaro, MD

1:50 p.m. - 2:55 p.m.  Personalized Medicine Approach to the Treatment of Advanced Prostate Cancer  
Moderator: Jeffrey M. Holzbeierlein, MD, FACS

3:55 p.m. - 4:00 p.m.  Questions and Discussion

1:50 p.m. - 2:00 p.m.  Application of Personalized Medicine to Prostate Cancer  
Ganesh Palapattu, MD, FACS

2:00 p.m. - 2:10 p.m.  What Genomic Research Tells Us about Treating Prostate Cancer  
James D. Brooks, MD

2:10 p.m. - 2:20 p.m.  AR Splice Variants as Prediction Tools in Advanced Prostate Cancer  
Emmanuel Antonarakis, MBCh

2:20 p.m. - 2:30 p.m.  Prostate Cancer Biomarkers for Tailored Therapy: Value Added or Only Cost?  
David F. Jarrard, MD

2:30 p.m. - 2:40 p.m.  The Changing Face of Prostate Cancer Treatment: ADT and Early Chemotherapy (CHAARTED trial)  
Christopher Sweeney, JM, BBS

2:40 p.m. - 2:55 p.m.  Panel Discussion: Are We Ready for Molecular Classification of All Tumors Prior to Treatment?  
Moderator: Jeffrey M. Holzbeierlein, MD, FACS  
Panelists: James D. Brooks, MD  
David F. Jarrard, MD  
Christopher Sweeney, JM, BBS  
Emmanuel Antonarakis, MBCh  
Ganesh Palapattu, MD, FACS

2:55 p.m. - 3:10 p.m.  Break

3:10 p.m. - 4:00 p.m.  Penile Cancer: New Approaches and Guidelines  
Moderator: Philippe E. Spiess, MSc, MD

3:10 p.m. - 3:20 p.m.  Updated NCCN Guidelines on Penile Cancer and Trials  
Speaker: Philippe E. Spiess, MSc, MD

3:20 p.m. - 3:30 p.m.  Primary Penile Sparing Treatment Approaches  
Adam S. Feldman, MD, MPH

3:30 p.m. - 3:40 p.m.  Management of Inguinal Lymph Nodes in Patients with High-Risk Primary Penile Tumors and No Palpable Adenopathy or Non-Bulky Lymph Nodes  
Viraj A. Master, MD, PhD, FACS

4:00 p.m. - 5:00 p.m.  Enhancing Post-Operative Recovery After Cystectomy for Bladder Cancer  
Moderator: Badrinath R. Konety, MD, MBA

4:00 p.m. - 4:10 p.m.  Quitting the Right Way: Evidence Based Tobacco Use Prevention  
Dorothy Hatsukami, PhD

4:10 p.m. - 4:20 p.m.  Patterns of Tobacco Use and Outcomes from Bladder Cancer - Policy Implications  
John L. Gore, MD, MS

4:20 p.m. - 4:30 p.m.  Guidelines for Perioperative Care after Radial Cystectomy for Bladder Cancer: Enhanced Recovery after Surgery (ERAS) Society  
Jay B. Shah, MD

4:30 p.m. - 4:40 p.m.  Intra-Operative Techniques to Enhance Post-Operative Outcomes  
George Thalmann, MD

4:40 p.m. - 4:50 p.m.  Preventing Readmissions following Cystectomy  
Ted A. Skolarus, MD, MPH

4:50 p.m. - 5:00 p.m.  Questions and Closing

Saturday, May 16, 2015  
SUO/SBUR Joint Meeting (Morning Program)  
NOMCC: La Nouvelle AB  
8:00 a.m. – 11:30 a.m.

SUO Business Meeting Luncheon (Members Only)  
NOMCC: Room 255-257  
11:30 a.m. – 12:30 p.m.

SUO Annual Meeting (Afternoon Program)  
NOMCC: La Nouvelle AB  
12:30 p.m. – 5:00 p.m.

SUO Reception with Awards and Announcements  
Hilton New Orleans Riverside  
Grand Salon C  
5:30 p.m. – 7:30 p.m.  Cocktail Reception  
5:45 p.m.  Awards and Announcements
SUO/SBUR Joint Meeting Educational Needs

(MORNING PROGRAM)
Emerging Paradigms in Metastasis
The Joint SUO/SBUR morning sessions at the AUA Annual Meeting will address emerging new evidence for distinct cellular processes that permit and promote cancer metastasis. Since most patients who succumb to cancer ultimately die from the metastatic disease, it is imperative to fully understand how this occurs in order to identify new therapeutic targets for effective treatments. Recent laboratory-based evidence has identified multiple processes that include tumor cell dormancy, tumor cell plasticity through epithelial-mesenchymal transition (EMT) and MET, circulating tumor cells, the metastatic niche and cancer stem cells. From these data, new drug targets and diagnostic approaches have arisen that may provide effective therapy, improved quality of life and expanded survival for patients. As such, there is a continuing need to keep abreast of these processes and therapeutic opportunities in the medical community. As such, the sessions will provide clinicians, medical oncologists, urologists, pathologists, radiologists and basic researchers with the latest updates on mTOR inhibitors for regulation of tumor dormancy, CTC measurements for monitoring metastatic spread, mechanisms of tumor dissemination, clonal origins of prostate cancer and the roles of cancer stem cells in evading therapy and promoting metastatic spread. The meeting is intended to cross talk between specialties and seed new concepts for future development of effective therapies in urologic oncology.

SUO/SBUR Educational Objectives
(MORNING PROGRAM)
At the conclusion of the session, participants should be able to:
1. Identify how tumor cells remain dormant at distant sites for extended times.
2. Describe the role of epithelial-mesenchymal transition (EMT) and fibroblasts in epithelial tumor dissemination and metastasis.
3. Explain the clinical relevance of circulating tumor cells and their utility in monitoring metastatic spread.
4. Recognize the importance of identifying the clonal origins of prostate cancer metastasis.
5. Explain the role of cancer stem cells in tumor progression and therapeutic relapse.

SUO Annual Meeting at the AUA Educational Needs
(AFTERNOON PROGRAM)
- Deficit in knowledge regarding workup and management of bladder cancer.
- Deficit in understanding regarding personalized medicine and its impact on prostate cancer treatment.
- Deficit in competence regarding management of locally advanced prostate cancer.
- Lack of knowledge regarding role of improving recovery after cystectomy in bladder cancer patients.

SUO Annual Meeting at the AUA Educational Objectives
(AFTERNOON PROGRAM)
At the conclusion of the meeting attendees should be able to:
1. Describe new approaches to imaging and detection of high-risk bladder cancer.
2. Review personalized medicine definitions and its approaches to advanced prostate cancer.
3. Explain the new trial on ADT and early chemotherapy for prostate cancer.
4. Identify the new NCCN guidelines for penile cancer.
5. Explain the role of neoadjuvant and adjuvant therapy for penile cancer.

AUA Accreditation Information
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this activity for the Society for Basic Urologic Research/Society of Urologic Oncology, Inc. Joint Morning Meeting for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation: The American Urological Association designates this activity for the Society of Urologic Oncology Afternoon Session for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician Health Professionals: The AUA is not accredited to offer credit for non-physician health professionals. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
MARK YOUR CALENDAR

16th Annual Meeting of the Society of Urologic Oncology
Wednesday, December 2 – Friday, December 4, 2015

YUO Dinner: Wednesday, December 2nd
SUO Reception: Thursday, December 3rd

Renaissance Washington DC Downtown Hotel
999 9th Street NW
Washington, DC 20001

SUO is happy to provide discounted room rates of $229.00 per night plus applicable tax at the Renaissance Washington DC Downtown Hotel. Please be sure to book your room early, as the block may sell out prior to the November 10, 2015 deadline.

Registration is now open! Go to tiny.cc/suo2015 to register today!

SUBMIT YOUR ABSTRACT FOR THE
16th ANNUAL MEETING Now through Friday, August 14, 2015
Only online at www.suonet.org
THANK YOU TO THE SUO 2014 – 2015 CORPORATE SPONSORS

Genentech
Genomic Health
Janssen Biotech
Medivation/Astellas
Memorial Sloan Kettering Cancer Center
Myriad Genetic Laboratories
Sanofi Oncology